Literature DB >> 23297120

The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010.

Andreas Maercker1, Axel Perkonigg, Martin Preisig, Karl Schaller, Michael Weller.   

Abstract

BACKGROUND: In 2005, findings of the first "cost of disorders of the brain in Europe" study of the European Brain Council (EBC) showed that these costs cause a substantial economic burden to the Swiss society. In 2010 an improved update with a broader range of disorders has been analysed. This report shows the new findings for Switzerland and discusses changes.
METHODS: Data are derived from the EBC 2010 census study that estimates 12-month prevalence of 12 groups of disorders of the brain and calculates costs (direct health-care costs, direct non-medical costs and indirect costs) by combining top-down and bottom up cost approaches using existing data.
RESULTS: The most frequent disorder was headache (2.3 million). Anxiety disorders were found in 1 million persons and sleep disorders in 700,000 persons. Annual costs for all assessed disorders total to 14.5 billion Euro corresponding to about 1,900 EUR per inhabitant per year. Mood, psychotic disorders and dementias (appr. 2 billion EUR each) were most costly. Costs per person were highest for neurological/neurosurgery-relevant disorders, e.g. neuromuscular disorders, brain tumour and multiple sclerosis (38,000 to 24,000 EUR).
CONCLUSION: The estimates of the EBC 2010 study for Switzerland provide a basis for health care planning. Increase in size and costs compared to 2005 are mostly due to the inclusion of new disorders (e.g., sleep disorders), or the re-definition of others (e.g., headache) and to an increase in younger cohorts. We suggest coordinated research and preventive measures coordinated between governmental bodies, private health-care and pharmaceutical companies.

Entities:  

Mesh:

Year:  2013        PMID: 23297120     DOI: 10.4414/smw.2013.13751

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  5 in total

Review 1.  Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.

Authors:  Alexander Konnopka; Hannah König
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

Review 2.  Cost of disorders of the brain in Spain.

Authors:  Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

3.  Effects of Aerobic Exercise as Add-On Treatment for Inpatients With Moderate to Severe Depression on Depression Severity, Sleep, Cognition, Psychological Well-Being, and Biomarkers: Study Protocol, Description of Study Population, and Manipulation Check.

Authors:  Christian Imboden; Markus Gerber; Johannes Beck; Anne Eckert; Uwe Pühse; Edith Holsboer-Trachsler; Martin Hatzinger
Journal:  Front Psychiatry       Date:  2019-04-25       Impact factor: 4.157

4.  The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Authors:  Giulio Disanto; Pascal Benkert; Johannes Lorscheider; Stefanie Mueller; Jochen Vehoff; Chiara Zecca; Simon Ramseier; Lutz Achtnichts; Oliver Findling; Krassen Nedeltchev; Ernst-Wilhelm Radue; Till Sprenger; Christoph Stippich; Tobias Derfuss; Jean-François Louvion; Christian P Kamm; Heinrich P Mattle; Christoph Lotter; Renaud Du Pasquier; Myriam Schluep; Caroline Pot; Patrice H Lalive; Özgür Yaldizli; Claudio Gobbi; Ludwig Kappos; Jens Kuhle
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

5.  Psychiatric In-Patients Are More Likely to Meet Recommended Levels of Health-Enhancing Physical Activity If They Engage in Exercise and Sport Therapy Programs.

Authors:  Janine Ehrbar; Serge Brand; Flora Colledge; Lars Donath; Stephan T Egger; Martin Hatzinger; Edith Holsboer-Trachsler; Christian Imboden; Nina Schweinfurth; Stefan Vetter; Markus Gerber
Journal:  Front Psychiatry       Date:  2018-07-20       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.